Asako Yoshizaki‐Ogawa

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba et al. · The Lancet Rheumatology · 2021 · 238 citations

Systemic Scleroderma, Systemic Treatment, Immunology +6

Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis

Ai Kuzumi, Ayumi Yoshizaki, Kazuki Matsuda et al. · Nature Communications · 2021 · 77 citations · Full text

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

Satoshi Ebata, Ayumi Yoshizaki, Koji Oba et al. · The Lancet Rheumatology · 2022 · 70 citations

Systemic Scleroderma, Systemic Treatment, Immunology +7

Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis

Kazuki Matsuda, Ayumi Yoshizaki, Ai Kuzumi et al. · The Journal of Dermatology · 2020 · 52 citations

B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis

Hiroko Numajiri, Ai Kuzumi, Takemichi Fukasawa et al. · Arthritis & Rheumatology · 2021 · 43 citations